Founded in 2015 in Stockholm, Sweden, EMPE Diagnostics emerged from the scientific excellence of the Karolinska Institute. We are dedicated to addressing the global burden of tuberculosis (TB) through diagnostics and research tools that are fast, accurate, and accessible.
Our mission goes beyond detection. By combining TB identification with antibiotic resistance profiling in a single test, we aim to stay ahead of antimicrobial resistance (AMR) and ensure patients receive the right treatment from the very first diagnosis.
Our vision is a world free from TB, enabled by timely, accessible diagnosis for everyone, everywhere.
With a strong focus on international markets, particularly in India—where more than 2.7 million new TB cases are reported each year—EMPE Diagnostics plays a vital role in the global fight against TB.
Our CDSCO-approved IVD product (India Regulatory Authorities), along with our expanding research use only portfolio, are manufactured at scale at our facility in Hyderabad.
We are proud to be ISO 13485:2016 certified and compliant with “Made in India” requirements, enabling participation in national programs and government tenders.
At the leading edge of medical innovation, we design, develop, and manufacture next-generation molecular diagnostics and research tools for rapid, highly accurate tuberculosis detection and genetic antimicrobial resistance profiling. At the core of our innovation is Pli-RCA, standing for Padlock probe-linked Rolling Circle Amplification, our molecular detection platform. Pli-RCA combines advanced padlock probe design with rolling circle amplification and specialized enzymatic biochemistry to enable highly sensitive and specific detection of resistance-associated mutations in Mycobacterium tuberculosis.
Our platforms are engineered for real-world impact: combining advanced molecular design with practical implementation, Pli-RCA bridges the gap between cutting-edge diagnostics and accessible global healthcare.
While our current focus is on tuberculosis, we are actively expanding the Pli-RCA pipeline across both infectious and non-infectious disease areas, enabling precise and accessible detection across a wide range of clinical challenges.
EMPE Diagnostics is proud to be supported by leading global organizations and investors who share our commitment to eliminating TB. We have received grant funding from both the European Innovation Council (EIC) and the Gates Foundation — becoming the first company to be backed by both these prestigious institutions.
Rapid Results
Actionable results in just a few hours
Internal Control Included
Monitors validity of assay set up and PCR inhibition
Compatible Platform
Designed for use on existing laboratory equipment
Efficient Workflow
Streamlined protocol for routine molecular laboratories
Improved diagnostic confidence
High Sensitivity & Specificity of results
Early Detection
Confirmation of TB disease ensuring faster treatment
